What Is 5-Amino-1MQ?

1. How does 5-Amino-1MQ work?

NNMT transfers a methyl group from S-adenosylmethionine, abbreviated SAM, onto nicotinamide, a form of vitamin B3. The products are 1-methylnicotinamide and S-adenosylhomocysteine. Nicotinamide can also enter the salvage pathway that recycles it into NAD+, a coenzyme involved in energy metabolism and cellular repair.

That creates two connections researchers can investigate. NNMT uses a potential NAD+ precursor, and it consumes methyl groups that cells also use elsewhere. Blocking the enzyme can change both processes. Describing NNMT as directly “breaking down NAD+” skips the actual reaction: its substrate here is nicotinamide.

In Kraus and colleagues’ 2014 Nature paper, reducing NNMT expression with antisense oligonucleotides protected mice against diet-induced obesity. Researchers linked the effect to higher energy expenditure and changes in adipose NAD+, SAM and polyamine metabolism. Polyamines are small molecules involved in cell function; making and processing them can consume metabolic fuel.

That experiment tested suppression of a gene’s expression. Researchers subsequently tested whether a small molecule could inhibit the enzyme’s activity and produce useful effects. 5-Amino-1MQ came from that drug-development work.

2. The 5-Amino-1MQ weight-loss study, in numbers

Neelakantan and colleagues’ paper appeared online in 2017 and in the January 2018 issue of Biochemical Pharmacology. Those two dates can make the same study look like two separate experiments in online summaries.

The obesity experiment included 18 male mice, nine per group, after 16 weeks on a high-fat diet. Researchers continued that diet and administered either saline or 5-Amino-1MQ by subcutaneous injection for 11 days.

The fat-pad result cannot be relabeled “35% total body-fat loss.” Researchers weighed a specific depot after treatment; they did not report a 35% reduction in each mouse’s whole-body fat from baseline. Likewise, the 5.1% weight decrease and the comparison against weight-gaining controls use different denominators.

Unchanged measured food intake supports investigating an effect beyond eating less. It does not demonstrate that people can take 5-Amino-1MQ, keep their usual calorie intake and reliably lose fat. Nine mice per group over 11 days cannot establish lasting effects, weight regain after withdrawal or outcomes in lean athletes.

Why the mouse dose is easy to misquote

The methods report 20 mg/kg per injection, three times daily. They also express the daily amount as approximately 34 mg/kg of the parent compound after accounting for the salt’s mass. These are two descriptions of the same experimental exposure.

Neither value supplies a human dose. Converting milligrams by body weight would still leave absorption, metabolism, tissue exposure and toxicity unanswered. The experiment also says nothing directly about whether an oral capsule reproduces those injection results.

Later mouse studies from the same group

Two later experiments extended the obesity work, again in mice given injections. In a 2024 study by Babula and colleagues, obese mice kept on a high-fat diet received saline, 10 mg/kg/day or 32 mg/kg/day once daily for about four weeks, eight per group. Only the higher dose limited gain: those mice gained 0.9 g, against 5.4 g on saline and 5.2 g on the lower dose. Food intake and lean mass showed no significant treatment effect. In that study the drug slowed weight gain rather than producing weight loss.

In a 2021 study by Sampson and colleagues, obese mice were switched to a lower-calorie lean diet. Over about seven weeks, those also given daily 5-Amino-1MQ injections lost about 6.3 g and about 29% of their fat mass from baseline, against about 2.9 g and 3% with the diet switch alone. Groups had six to eight mice.

These papers come from the developer’s group; they declare that the senior author founded Ridgeline Therapeutics, a company developing NNMT inhibitors.

3. Which studies concern the compound, the target or people?

NNMT research spans genetic experiments, several drug candidates and measurements in human tissue. A paper about NNMT is not automatically a treatment study of 5-Amino-1MQ.

The human study by Kannt and colleagues found approximately twice as much NNMT expression in two types of white adipose tissue in participants with type 2 diabetes compared with controls. Exercise and bariatric surgery were associated with lower adipose NNMT expression. Nobody in that study received 5-Amino-1MQ.

For this guide, searches of PubMed, Europe PMC and ClinicalTrials.gov used the short name and related chemical terminology. On October 15, 2026, the registry returned no matches for “5-amino-1MQ” or “5-amino-1-methylquinolinium”; the literature reviewed did not identify a published human treatment trial. These searches describe the public evidence found, without ruling out unpublished work or studies registered under other names.

4. NAD+, energy and longevity claims

In the original fat-cell experiments, NAD+ measurements were roughly 1.2–1.6 times those in untreated cells across the tested 1–60 micromolar concentration range. The individual comparison reached statistical significance at 10 micromolar. These were cultured mouse adipocytes, so “raises NAD+ by 60%” would need that context attached.

An increase in a cellular coenzyme does not quantify how energetic a person feels, their exercise performance or their lifespan. The studies reviewed here do not establish human improvements in fatigue, VO₂ max, biological age or survival from taking 5-Amino-1MQ.

NMN and NR enter NAD+ precursor pathways, while 5-Amino-1MQ inhibits an enzyme that uses nicotinamide. The mechanisms make combinations a research question. They do not establish that stacking these compounds raises useful tissue NAD+ more effectively or produces better health outcomes. A change in a blood marker would also need evidence connecting it to the outcome someone wants.

5. Muscle preservation, recovery and bodybuilding

The 2019 muscle paper tested 24-month-old male mice. Researchers injured the tibialis anterior, a lower-leg muscle, with barium chloride and examined recovery with NNMT inhibition. Treatment began before the injury.

Treated mice had greater muscle stem-cell activity and larger regenerating fibers. The paper reported about 70% higher peak torque in the injured muscle compared with controls. Torque measures rotational force; here it assessed recovery of muscle function after a controlled chemical injury.

A 2024 study gave 35 female mice aged 22 months saline or 10 mg/kg/day by injection for eight weeks, with or without weighted wheel running. Compared with sedentary controls, grip strength was about 40% higher with the drug alone, 20% higher with exercise alone and 60% higher with both. Mice assigned to the drug started roughly 10% heavier because randomization was by cage.

Those results give researchers a reason to investigate age-related muscle problems. They cannot predict a 70% strength increase in a healthy lifter. Neither experiment tested hypertrophy from resistance training in young, healthy animals, soreness after a workout or preservation of lean mass while using a GLP-1 drug. In the 2024 obesity study, lean mass showed no significant treatment effect.

For body recomposition, the missing experiment would measure fat mass, lean mass and performance during a defined calorie deficit. A lower scale weight in obese mice and better repair in a separate injury study cannot jointly establish muscle-sparing fat loss in people.

6. Oral 5-Amino-1MQ, injections and half-life

The original paper included artificial-membrane and intestinal-cell permeability tests. Those assays help screen whether molecules can cross barriers, but cannot measure how much of a swallowed dose reaches human circulation or adipose tissue.

A separate 2018 Kannt study reported about 40% oral bioavailability in mice for JBSNF-000088. That molecule is a different NNMT inhibitor. Its absorption and roughly 0.4-hour apparent oral half-life cannot be assigned to 5-Amino-1MQ.

Animal pharmacokinetic studies have since measured 5-Amino-1MQ itself. In rats, a 2021 study reported mean terminal half-lives of about 3.8 hours after intravenous and 6.9 hours after oral dosing, with 38.4% oral bioavailability. In mice, the 2024 Babula study found only about 3.5% oral bioavailability after a 30 mg/kg dose, which the authors attributed to limited gut absorption and heavy first-pass metabolism in the liver. Mouse half-lives were about 6.3 hours intravenously, about 13 hours subcutaneously and 14.8 hours orally, yet plasma levels after injection stayed above the concentration needed to inhibit half of mouse NNMT for only about 2–4 hours. The two species disagree, and neither establishes absorption in people.

The evidence reviewed here does not establish a human oral or injected half-life for 5-Amino-1MQ. There is consequently no validated basis for a once-daily schedule, split dosing, a loading phase or a particular cycle length. A half-life calculator can model an assumption; it cannot supply the missing pharmacokinetic study.

7. Side effects and safety gaps

The short obesity study reported no observable adverse effects under its experimental conditions. That observation is useful for early drug development, but cannot estimate how often a person might develop an adverse effect or whether months of exposure would be tolerated.

Reliable human adverse-event rates, interaction studies and reproductive safety data were not established in the research reviewed. Lists of supposedly “common” side effects copied from sellers or forums have no controlled denominator. Absence of a dependable side-effect list leaves uncertainty about risk.

NNMT participates in both nicotinamide and methyl-group metabolism. The mechanistic research describes changes in SAM availability and histone methylation, chemical modifications involved in gene regulation. That makes the biological effects broader than one fat-loss measurement. It does not, by itself, prove benefit or harm from chronic human inhibition.

The 2024 mouse study also reported two signals. In an off-target screening panel at 10 micromolar, 5-Amino-1MQ inhibited monoamine oxidase A, an enzyme that breaks down serotonin, norepinephrine and dietary tyramine, by 67.4%. The higher dose lowered white blood cell counts, with lymphocytes 31% and monocytes 50% below controls. The authors interpreted these changes favorably; their relevance to people has not been studied.

Product testing answers a separate question. A certificate of analysis may provide information about the tested sample’s identity or purity, depending on its methods. It cannot establish an effective human dose, clinical safety or the sterility of an injectable preparation unless those properties were specifically assessed.

8. 5-Amino-1MQ vs GLP-1 drugs, MOTS-c and NAD+ precursors

No controlled human evidence identified here establishes added benefit or safety from combining 5-Amino-1MQ with semaglutide, tirzepatide or retatrutide. Claims about breaking a plateau, preserving muscle or preventing metabolic adaptation remain untested for those combinations.

Before-and-after photos cannot resolve that uncertainty. Changes in diet, training, other compounds, hydration and starting body fat can all affect the apparent result. A useful human trial would specify the formulation and dose, compare treatment against a control, measure body composition and collect adverse events. For a muscle-preservation claim, it would also need lean-mass and strength outcomes during weight loss.

9. 5-Amino-1MQ FAQ

• What is 5-Amino-1MQ used for?

  Researchers use 5-Amino-1MQ to investigate NNMT inhibition, fat metabolism and muscle regeneration. People discuss it for fat loss, NAD+ support and body recomposition, but those benefits have not been established in human treatment trials.

• Is 5-Amino-1MQ a peptide?

  No. 5-Amino-1MQ is 5-amino-1-methylquinolinium, a small molecule commonly studied as an iodide salt. It has no chain of amino acids, even though sellers often group it with peptides.

• How much weight can you lose with 5-Amino-1MQ?

  There is no established human weight-loss estimate. A short mouse study reported about 5.1% weight loss from baseline after 11 days of injections. That result cannot predict pounds lost by a person or the effects of oral capsules.

• Does 5-Amino-1MQ increase NAD+?

  Researchers measured increased NAD+ in cultured mouse fat cells exposed to 5-Amino-1MQ. The result supports a cellular mechanism; it does not establish increased NAD+ in human muscle, better energy or longer life after taking it.

• What is the recommended 5-Amino-1MQ dosage?

  No clinically validated human dose, cycle or titration schedule has been established. Mouse injection doses and doses advertised for capsules cannot supply a tested human regimen.

• Does oral 5-Amino-1MQ work?

  The original paper included laboratory membrane-permeability tests, but its obesity experiment used injections. This guide found no human oral study establishing absorption, fat loss or an effective capsule dose. In animals, oral bioavailability was about 38% in rats but only about 3.5% in mice.

• What are the side effects of 5-Amino-1MQ?

  Reliable human side-effect frequencies and long-term safety data are unavailable. Short mouse studies reported no obvious adverse effects under their conditions; they cannot establish the safety of repeated human use. A 2024 mouse study also reported inhibition of the enzyme MAO-A in a laboratory screen and lower white blood cell counts at the higher dose.

• What is the half-life of 5-Amino-1MQ?

  A dependable human elimination half-life has not been established in the research reviewed here. Animal studies reported plasma half-lives of about 3.8–6.9 hours in rats and about 6–15 hours in mice, depending on route. Those values, a laboratory permeability result or a half-life from a different NNMT inhibitor cannot determine a human dosing interval.

• Can you stack 5-Amino-1MQ with tirzepatide or retatrutide?

  The reviewed evidence does not establish the safety or added benefit of either combination. Different proposed mechanisms do not demonstrate extra fat loss, muscle preservation or a safe dose ratio.

10. Sources